

# Luigi Francesco Iannone

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8903388/publications.pdf>

Version: 2024-02-01

29  
papers

695  
citations

567281  
15  
h-index

580821  
25  
g-index

30  
all docs

30  
docs citations

30  
times ranked

853  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neuronal and non-neuronal TRPA1 as therapeutic targets for pain and headache relief. <i>Temperature</i> , 2023, 10, 50-66.	3.0	3
2	Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine. <i>European Journal of Neurology</i> , 2022, 29, 1505-1513.	3.3	25
3	The microbiota-gut-brain axis and epilepsy from a multidisciplinary perspective: Clinical evidence and technological solutions for improvement of in vitro preclinical models. <i>Bioengineering and Translational Medicine</i> , 2022, 7, .	7.1	10
4	Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score. <i>CNS Drugs</i> , 2022, 36, 191-202.	5.9	32
5	Status epilepticus in pregnancy: a literature review and a protocol proposal. <i>Expert Review of Neurotherapeutics</i> , 2022, 22, 301-312.	2.8	12
6	Emerging Pharmacological Treatments for Migraine in the Pediatric Population. <i>Life</i> , 2022, 12, 536.	2.4	6
7	Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine. <i>Cephalalgia</i> , 2022, 42, 1323-1330.	3.9	18
8	First evidence of altered microbiota and intestinal damage and their link to absence epilepsy in a genetic animal model, the WAG/Rij rat. <i>Epilepsia</i> , 2021, 62, 529-541.	5.1	35
9	Appropriate use of generic and branded antiepileptic medications in epilepsy: Updated recommendations from the Italian League Against Epilepsy (LICE). <i>Epilepsy and Behavior</i> , 2021, 116, 107804.	1.7	7
10	Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?. <i>Gastric Cancer</i> , 2021, 24, 765-779.	5.3	12
11	Assessing knowledge and attitudes toward epilepsy among schoolteachers and students: Implications for inclusion and safety in the educational system. <i>PLoS ONE</i> , 2021, 16, e0249681.	2.5	4
12	Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice. <i>Frontiers in Pharmacology</i> , 2021, 12, 684638.	3.5	33
13	Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox-Gastaut Syndrome. <i>Frontiers in Neurology</i> , 2021, 12, 673135.	2.4	23
14	Pharmacology of Cenobamate: Mechanism of Action, Pharmacokinetics, Drug-Drug Interactions and Tolerability. <i>CNS Drugs</i> , 2021, 35, 609-618.	5.9	34
15	Renal denervation for resistant hypertension. <i>The Cochrane Library</i> , 2021, 2021, CD011499.	2.8	9
16	Clinically relevant drug interactions between statins and antidepressants. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 227-239.	1.5	24
17	A Rare Case of Drug-Induced Erectile Dysfunction with Secukinumab Solved After Switch to Ixekizumab in A Psoriatic Patient: A Case Report. <i>Current Drug Safety</i> , 2020, 15, 69-72.	0.6	7
18	Management of status epilepticus in patients with liver or kidney disease: a narrative review. <i>Expert Review of Neurotherapeutics</i> , 2020, 21, 1-14.	2.8	4

#	ARTICLE	IF	CITATIONS
19	The efficacy of perampanel as adjunctive therapy in drug-resistant focal epilepsy in a “real world” context: focus on temporal lobe epilepsy. <i>Journal of the Neurological Sciences</i> , 2020, 415, 116903.	0.6	18
20	Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy. <i>Current Medical Research and Opinion</i> , 2020, 36, 1457-1463.	1.9	40
21	The potential role of interventions impacting on gut-microbiota in epilepsy. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 423-435.	3.1	25
22	Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study. <i>PLoS ONE</i> , 2020, 15, e0241575.	2.5	38
23	Microbiota-gut brain axis involvement in neuropsychiatric disorders. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 1037-1050.	2.8	116
24	Can we “seize” the gut microbiota to treat epilepsy?. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 107, 750-764.	6.1	60
25	Gut microbiota and psychogenic non-epileptic seizures: i can feel it in the belly. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 1165-1165.	2.8	2
26	Pharmacology of new and developing intravenous therapies for the management of seizures and epilepsy. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 25-39.	1.8	6
27	Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers induced pemphigus: A case series and literature review. <i>Dermatologic Therapy</i> , 2019, 32, e12748.	1.7	23
28	Pharmacokinetic Interactions of Clinical Interest Between Direct Oral Anticoagulants and Antiepileptic Drugs. <i>Frontiers in Neurology</i> , 2018, 9, 1067.	2.4	60
29	Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP). <i>PLoS ONE</i> , 2018, 13, e0205134.	2.5	9